Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R.A. SCORE: Rituximab for inhibition of joint structural damage in rheumatoid arthritis
2007-001585-33Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Rituximab 1000 mg x 2 with Placebo (2 arms). Primary endpoint: Change in MRI bone erosion score (RAMRIS) from baseline to week 24. Started Jul 2007; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-001585-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-001585-33.